Nihon University School of Medicine - summitMD.com

More documents

Recommendations

Info

Background Therefore, it has been emphasized that treatment to achieve lesion stability and/or regression is beneficial. Large primary and secondary prevention trials with Statin have demonstrated that lipid-lowering therapy was effective or preventing cardiac events. Nihon University School of Medicine
Background Recent studies show that 1) Aggressive LDL-C lowering with HMG-CoA reductase inhibition, atorvastatin, likely leads to a slowdown of plaque growth and a change in plaque composition.(GAIN) 2) Reversal study 3) Probucol has been reported to prevent atherogenesis by acting as an anti-oxidant and suppressing the oxidative modification of LDL-C and Probucol could stabilize plaque. M. Schartl et al. Circulation; 104:387 Y. Sasayama et al. JACC; 39:610 Nihon University School of Medicine
Page 1 and 2: Role of lipid-lowering therapy Aggr
Page 3: Such lesions frequently appear as n
Page 7 and 8: REVERSAL trial 1. 654 patients enro
Page 9 and 10: Background Recent studies show that
Page 11 and 12: Purpose To evaluate the combined ef
Page 13 and 14: Methods: Study Design Medication: G
Page 15 and 16: Texture Videodensitometric Analysis
Page 17 and 18: Patient Characteristics Group A Gro
Page 19 and 20: Changes in LDL-C 200 150 100 50 * *
Page 21 and 22: % change in Lumen volume *
Page 23 and 24: % changes in plaque echogenicity (%
Page 25 and 26: Changes in Plaque Area and Echogeni
Page 27 and 28: Summary 1. Increase in echogenicity

Nihon University School of Medicine - summitMD.com

Create successful ePaper yourself

Delete template?

Save as template?